Published in Dtsch Med Wochenschr on July 01, 2008
Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol (2010) 0.98
Greek Physicians' Perceptions on Generic Drugs in the Era of Austerity. Scientifica (Cairo) (2015) 0.75
[Medical problems and risks with the discount contract law changeover of inhalers in Germany]. Dtsch Med Wochenschr (2008) 0.75
Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 4.59
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther (2013) 2.15
Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid. Int J Clin Pharmacol Ther (2007) 1.38
Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet (1995) 1.35
Timing of invasive procedures in therapy for primary and secondary spontaneous pneumothorax. Arch Surg (1991) 1.33
Patient-specific electronic decision support reduces prescription of excessive doses. Qual Saf Health Care (2010) 1.28
Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther (2010) 1.19
The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol (2006) 1.16
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther (2011) 1.15
Drug dosage in patients with renal failure optimized by immediate concurrent feedback. J Gen Intern Med (2001) 1.15
Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet (1998) 1.07
CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther (2007) 1.05
Clinical diagnosis of malaria and the risk of chloroquine self-medication in rural health centres in Burkina Faso. Trop Med Int Health (2008) 1.04
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J (2011) 1.04
Academic detailing improves identification and reporting of adverse drug events. Pharm World Sci (1999) 1.03
Role of nitric oxide in the regulation of the mechanical properties of peripheral conduit arteries in humans. Hypertension (1997) 1.03
Prospective pilot intervention study to prevent medication errors in drugs administered to children by mouth or gastric tube: a programme for nurses, physicians and parents. Qual Saf Health Care (2010) 1.00
Reversible ageusia associated with losartan. Lancet (1996) 0.99
Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients. Graefes Arch Clin Exp Ophthalmol (1997) 0.98
Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis (2004) 0.97
Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels. Thromb Haemost (1997) 0.96
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos (2010) 0.95
Evidence for disturbed S-adenosylmethionine : S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions? Nephrol Dial Transplant (1998) 0.94
Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol (1996) 0.93
Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther (2011) 0.93
[Information on medications - How do chronically ill patients assess counselling on drugs in general practice?]. Dtsch Med Wochenschr (2009) 0.90
Methylenetetrahydrofolate reductase polymorphism, plasma homocysteine and age. Eur J Clin Invest (1999) 0.89
Functional activity and transmembrane signaling mechanisms after cryopreservation of human internal mammary arteries. J Vasc Surg (1998) 0.88
Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity. Clin Pharmacol Ther (2009) 0.88
Severe hypotension and bradycardia associated with verapamil and clarithromycin. Am J Health Syst Pharm (1998) 0.87
Neurokinin-1 receptor antagonist R116301 inhibits substance P-induced venodilation. Clin Pharmacol Ther (1999) 0.87
Influence of oral S-adenosylmethionine on plasma 5-methyltetrahydrofolate, S-adenosylhomocysteine, homocysteine and methionine in healthy humans. J Pharmacol Exp Ther (1997) 0.87
Effect of methionine loading on 5-methyltetrahydrofolate, S-adenosylmethionine and S-adenosylhomocysteine in plasma of healthy humans. Clin Sci (Lond) (1996) 0.87
Tablet splitting: patients and physicians need better support. Eur J Clin Pharmacol (2007) 0.86
Auditory and electroencephalographic effects of midazolam and alpha-hydroxy-midazolam in healthy subjects. Br J Clin Pharmacol (2000) 0.86
Disturbed ratio of erythrocyte and plasma S-adenosylmethionine/S-adenosylhomocysteine in peripheral arterial occlusive disease. Atherosclerosis (2001) 0.86
Substance P in human hand veins in vivo: tolerance, efficacy, potency, and mechanism of venodilator action. Clin Pharmacol Ther (1996) 0.86
Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol (2000) 0.86
Patient knowledge on oral anticoagulants: results of a questionnaire survey in Germany and comparison with the literature. Int J Clin Pharmacol Ther (2008) 0.85
Overconsumption detected by electronic drug monitoring requires subtle interpretation. Clin Pharmacol Ther (2000) 0.85
Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). BMJ (1990) 0.85
Role of basal and stimulated release of nitric oxide in the regulation of radial artery caliber in humans. Hypertension (1995) 0.85
[HeiCare®: a project aiming to improve medication communication across health care sectors]. Dtsch Med Wochenschr (2011) 0.84
N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther (1996) 0.84
Evaluation of conventional chest tube therapy for iatrogenic pneumothorax. Chest (1993) 0.84
[Use and potential risks of over-the-counter analgesics]. Schmerz (2014) 0.84
Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther (2001) 0.83
Risk of cataract in patients treated with statins. Arch Intern Med (2001) 0.82
Design and evaluation of an ontology-based drug application database. Methods Inf Med (2010) 0.82
[Tablet splitting]. Ther Umsch (2006) 0.82
Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis (1999) 0.82
Functional recovery of human mesenteric and coronary arteries after cryopreservation at -196 degrees C in a serum-free medium. J Vasc Surg (1997) 0.82
Responsiveness to bradykinin in veins of hypercholesterolemic humans. Circulation (1993) 0.82
Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol (1999) 0.81
Discussion of "Attitude of physicians towards automatic alerting in computerized physician order entry systems". Methods Inf Med (2013) 0.80
Memorandum on the use of information technology to improve medication safety. Methods Inf Med (2014) 0.80
Influence of intensive physical training on urinary nitrate elimination and plasma endothelin-1 levels in patients with congestive heart failure. J Cardiopulm Rehabil (1999) 0.80
Isoniazid plus sulphadoxine-pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: a controlled clinical trial. Chemotherapy (2000) 0.80
Detection and prevention of prescriptions with excessive doses in electronic prescribing systems. Eur J Clin Pharmacol (2007) 0.79
[Tablets in stool? A common problem!]. Schweiz Med Wochenschr (1999) 0.79
[Conviction as a basis for compliance and strategies for improving compliance]. Schweiz Med Wochenschr (1999) 0.79
Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers. Allergy (1997) 0.79
Indirect evidence for stimulation of nitric oxide release by tumour necrosis factor-alpha in human veins in vivo. Cardiovasc Res (1995) 0.79
Cytochrome P450-3A phenotyping using midazolam is not altered by OATP1B1 polymorphisms. Clin Pharmacol Ther (2013) 0.79
Subconstrictor doses of neuropeptide Y potentiate alpha 1-adrenergic venoconstriction in vivo. Hypertension (1996) 0.78
[Prerequisites for electronic systems evaluating safe and effective drug therapy. A contribution to the Action Plan of the Federal Health Ministry]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2011) 0.78
Optimizing information on drug exposure by collection of package code information in questionnaire surveys. Pharmacoepidemiol Drug Saf (2007) 0.78
Correlation between apolipoprotein B and endothelin-1-induced vasoconstriction in humans. Peptides (2000) 0.77
More than just crushing: a prospective pre-post intervention study to reduce drug preparation errors in patients with feeding tubes. J Clin Pharm Ther (2015) 0.77
Acetaminophen is an inhibitor of hepatic N-acetyltransferase 2 in vitro and in vivo. Pharmacogenetics (1998) 0.77
The mechanism of cryoinjury: In vitro studies on human internal mammary arteries. Br J Pharmacol (2000) 0.77
Neuropeptide Y in human hand veins: pharmacologic characterization and interaction with cyclic guanosine monophosphate-dependent venodilators in vivo. Clin Pharmacol Ther (1995) 0.77
Safety and efficacy of a two-compartment Bayesian feedback program for therapeutic tobramycin monitoring in the daily clinical use and comparison with a non-Bayesian one-compartment model. Ther Drug Monit (1998) 0.76
Inspired oxygen fraction after cardiopulmonary bypass: effects on pulmonary function with regard to endothelin-1 concentrations and venous admixture. Br J Anaesth (2000) 0.76
[Clinico-pharmacological case (4). Epileptic seizure as an unwanted drug effect on theophylline poisoning]. Praxis (Bern 1994) (1996) 0.76
Recurrent ventricular fibrillation in mianserin intoxication. BMJ (1991) 0.75
Human neuropeptide Y potentiates alpha1-adrenergic blood pressure responses in vivo. Am J Physiol (1998) 0.75
Medication safety through e-health technology: can we close the gaps? Br J Clin Pharmacol (2013) 0.75
Local effect of transdermal isosorbide dinitrate ointment on hand vein diameter. Eur J Clin Pharmacol (2001) 0.75
L-arginine in the clinical arena: tool or remedy? Circulation (1993) 0.75
A systematic comparison of four different workup procedures for systematic toxicological analysis of urine samples using gas chromatography-mass spectrometry. Anal Bioanal Chem (2008) 0.75
[Drug interactions with the cytochrome P-450 system]. Dtsch Med Wochenschr (2000) 0.75
[Treatment of pulmonary arterial hypertension (PAH): recommendations of the Cologne Consensus Conference 2010]. Dtsch Med Wochenschr (2010) 0.75
[Anticonvulsant hypersensitivity syndrome. 2 case reports and an overview]. Praxis (Bern 1994) (1999) 0.75
[Drugs during pregnancy and breastfeeding: new risk categories--antibiotics as a model]. Dtsch Med Wochenschr (2006) 0.75
[Drug interactions]. Internist (Berl) (2010) 0.75
[Clinically relevant adverse drug interactions]. Ther Umsch (2000) 0.75
[Patient recruitment in clinical studies]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2009) 0.75
[Framework for biomedical research involving human subjects - algorithms for planning and organisation]. Dtsch Med Wochenschr (2002) 0.75
Pharmacokinetics and pharmacodynamics of clomethiazole after oral and rectal administration in healthy subjects. Clin Ther (1999) 0.75
Standardized documentation of drug recommendations in discharge letters--a contribution to quality management in cooperative care. Methods Inf Med (2006) 0.75
[Consideration of drug absorption in customizing drug therapy]. Ther Umsch (2000) 0.75